Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

NCT03591965 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
73
Enrollment
INDUSTRY
Sponsor class

Stopped Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study

Conditions

Interventions

Sponsor

Antengene Therapeutics Limited